80042
document
Comparison of antihypertensive effects of captopril and propranolol in essential hypertension . The antihypertensive effects of the oral converting enzyme inhibitor captopril and of propranolol were evaluated in a single-blind trial of 12 weeks in 19 ambulatory men with moderated essential hypertension ( supine diastolic blood pressure [ DPB ] , 100 to 120 mm Hg after receiving placebo for two weeks ) whose sodium intake was unrestricted . The captopril group included 12 patients and the propranolol group seven . After the initial dose-finding period of four weeks , supine DBP was significantly reduced in eight patients receiving captopril and in four of the patients receiving propranolol . In these patients DBP decreased throughout the following eight weeks . In the remaining patients from each group , DBP was not reduced by either drug given alone at maximum allowable dosages during dose-finding periods , nor by combined administration in following weeks . No adverse side effects attributable to captopril were noted , except in one patient in whom proteinuria developed after seven weeks . Captopril has potential value in the treatment of moderate essential hypertension .
80043
Intervention_Pharmacological
captopril
80044
Intervention_Pharmacological
propranolol
80045
Intervention_Pharmacological
captopril
80046
Intervention_Pharmacological
propranolol
80047
Intervention_Control
placebo
80048
Intervention_Pharmacological
captopril
80049
Intervention_Pharmacological
propranolol
80050
Intervention_Pharmacological
captopril
80051
Intervention_Pharmacological
propranolol
80052
Intervention_Pharmacological
captopril
80053
Intervention_Pharmacological
Captopril
80054
Outcome_Physical
antihypertensive effects
80055
Outcome_Physical
( supine diastolic blood pressure [ DPB ]
80056
Outcome_Physical
supine DBP
80057
Outcome_Physical
DBP
80058
Outcome_Physical
DBP
80059
Outcome_Adverse-effects
No adverse side effects
80060
Outcome_Adverse-effects
proteinuria